Quantifying payloads of antibody‒drug conjugates using a postcolumn infused-internal standard strategy with LC‒MS
- 25 March 2024
- journal article
- research article
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1303, 342537
Abstract
No abstract availableKeywords
Funding Information
- National Taiwan University
This publication has 34 references indexed in Scilit:
- Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab DeruxtecanClinical Pharmacology & Therapeutics, 2021
- Antibody–drug conjugates: Recent advances in linker chemistryActa Pharmaceutica Sinica B, 2021
- Sacituzumab Govitecan: First ApprovalDrugs, 2020
- Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MSAnalytica Chimica Acta, 2018
- Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokineticsCancer, 2017
- Antibody-drug conjugates: recent advances in conjugation and linker chemistriesProtein & Cell, 2016
- Current ADC Linker ChemistryPharmaceutical Research, 2015
- Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction TherapyTransplantation and Cellular Therapy, 2015
- Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariatesCancer Chemotherapy and Pharmacology, 2014
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancerCancer Chemotherapy and Pharmacology, 2012